Topics

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

02:00 EST 4 Dec 2018 | National Cancer Institute

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.

Original Article: Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

NEXT ARTICLE

More From BioPortfolio on "Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...